NCT05206877

Topical Insulin for Glaucoma

Topical Insulin for Glaucoma and Optic Neuropathies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	Insulin, 4 units	Topical insulin 100 U/ml, 1 drop per day
DRUG	Insulin, 20 units	Topical insulin 500 U/ml, 1 drop per day
DRUG	insulin, 4 units twice daily	1 drop of low dose insulin twice daily.
DRUG	insulin, 20 units twice daily	1 drop of high dose insulin twice daily
DRUG	insulin, 4 units three times daily	1 drop of low dose insulin three times daily.
DRUG	insulin, 20 units three times daily	1 drop of high dose insulin three times daily.

Timeline

• Start date: 2022-04-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2022-01-25
• Last updated: 2025-11-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study